Assessment of lymphocytic function in vitro stimulated by specific tumor polypeptide combined with dendritic cells

  • Duo YANG ,
  • Xin-na ZHOU ,
  • Shuo WANG ,
  • Xiao-li WANG ,
  • Yan-hua YUAN ,
  • Hua-bin YANG ,
  • Hui-zhen GENG ,
  • Bing PENG ,
  • Zi-bo LI ,
  • Bin LI ,
  • Jun REN
Expand
  • 1. Department of Oncology, Beijing Shijitan Hospital, Capital Medical University Beijing Key Laboratory of Therapeutic Vaccines, Beijing 100038, China
    2. Hebei Bio-High Technology Company Limited, Shijiazhuang 050035, China

Received date: 2021-02-04

  Online published: 2021-12-13

Supported by

Special Project for the Construction of International Science and Technology Cooperation Base of Hebei Innovation Capability Improvement Plan Project(19392411D)

Abstract

Objective: To assess the activation function of specific tumor polypeptide for dendritic cell vaccine on lymphocytes proliferation, production of cytokines and killing activity in vitro by using dendritic cells as antigen presenting vector. Methods: Peripheral blood dendritic cells (DC) and cytokine-induced killer (CIK) were isolated and cultured by adherent culture method; CCK-8 method was used to assess the proliferation function of lymphocytes and the killing function of lymphocytes to tumor cells; enzyme-linked immunospot assay method was used to evaluate the secretion function of cytokines. The experiment was divided into tumor polypeptide group (peptide with DC-CIK), DC-CIK group and CIK group. Results: With presence of interleukin-2 (IL-2) in the culture system, the lymphocyte proliferation of the three groups was obvious. The absorbance at 450 nm of tumor polypeptide group was significantly higher than that of CIK group at the time points day 4 and day 6 (day 4: Z=-3.79, P<0.001; day 6: Z =-2.95, P< 0.01). The absorbance at 450 nm of group tumor polypeptide was significantly higher than that of DC-CIK group on day 4 (Z=-2.02, P<0.05). Without IL-2 in the culture system, lymphocytes proliferated slowly in all the three groups, and there was no significant difference in 450 nm absorbance at each time point. The levels of IL-4 (Z=-2.61, P< 0.01), granulocyte-macrophage colony-stimulation factor (GM-CSF, Z=-3.85, P< 0.001), interferon- γ (IFN- γ, Z=-3.56, P< 0.001) and tumor necrosis factor-α (TNF-ɑ, Z=-3.40, P< 0.001) of tumor polypeptide group were higher than those of CIK group. There was no significant difference in the production of cytokines except IL-4 (Z=-2.15, P< 0.05) when tumor polypeptide group was compared with DC-CIK group. The production of IFN-γ (Z=-2.44, P<0.05), TNF-ɑ (Z=-2.26, P< 0.05) and GM-CSF (Z=-3.73, P< 0.001) in DC-CIK group were higher than those of CIK group. Although there was no significant difference in killing activity between tumor polypeptide group, DC-CIK group and CIK group at hour 18 and hour 24, and the killing activity of tumor polypeptide group was higher than that of the other two groups. Conclusion: Tumor peptide combined with dendritic cells can improve the proliferation activity of CIK cells in vitro, and increase the secretion of several cytokines.

Cite this article

Duo YANG , Xin-na ZHOU , Shuo WANG , Xiao-li WANG , Yan-hua YUAN , Hua-bin YANG , Hui-zhen GENG , Bing PENG , Zi-bo LI , Bin LI , Jun REN . Assessment of lymphocytic function in vitro stimulated by specific tumor polypeptide combined with dendritic cells[J]. Journal of Peking University(Health Sciences), 2021 , 53(6) : 1094 -1098 . DOI: 10.19723/j.issn.1671-167X.2021.06.015

References

[1] 黄芸, 高建鹏, 王辉. 肿瘤疫苗临床研究评价及进展[J]. 肿瘤学杂志, 2019, 25(3):196-201.
[2] 沈季敏, 刘欣. 基于树突状细胞的肿瘤免疫治疗临床应用方式的研究进展[J]. 临床血液学杂志, 2018, 31(1):62-65.
[3] 邵小钧, 席庆. 精准医疗: 肿瘤诊治的新模式[J]. 现代肿瘤医学, 2016, 24(4):675-677.
[4] Jang GY, Kim YS, Lee SE, et al. Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors[J]. Cancer Immunol Immunother, 2021, 70(4):1075-1088.
[5] Jiang N, Qiao G, Wang X, et al. Dendritic cell/cytokine-induced killer cell immunotherapy combined with s-1 in patients with advanced pancreatic cancer: A prospective study[J]. Clin Cancer Res, 2017, 23(17):5066-5073.
[6] Calmeiro J, Carrascal MA, Tavares AR, et al. Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview[J/OL]. Pharmacol Res, 2021, 164: 105309[2021-01-01]. https://doi.org/10.1016/j.phrs.2020.105309.
[7] Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy[J/OL]. Nat Commun, 2019, 10(1): 5408[2021-01-01]. https://doi.org/10.1038/s41467-019-13368-y.
[8] 黄聪, 白丽. 树突状细胞肿瘤疫苗及其联合应用的研究进展[J]. 细胞与分子免疫学杂志, 2019, 35(12):1141-1145.
[9] Zhou JY, Alvarez CA, Cobb BA, Integration of IL-2 and IL-4 signals coordinates divergent regulatory T cell responses and drives therapeutic efficacy[J/OL]. Elife, 2021, 10: e57417(2021-02-22)[2021-03-01]. https://doi.org/10.7554/eLife.57417.
[10] 于甜, 胡小鹏, 祝小红, 等. 干扰素及肿瘤坏死因子抗病毒作用研究进展[J]. 中国免疫学杂志, 2014, 30(3):409-415.
[11] 马守宝, 林丹丹, 刘海燕. 炎症细胞因子在肿瘤微环境中的作用及其作为治疗靶点的研究进展[J]. 生命科学, 2016, 28(2):182-191.
[12] 林雨虹, 吕合作, 吴俊英. GM-CSF/IL-3/IL-5的免疫调节作用[J]. 中国免疫学杂志, 2019, 35(4):500-504.
[13] 姜南雁, 唐隽, 徐云升. GM-CSF在肿瘤免疫治疗中的作用最新研究进展[J]. 免疫学杂志, 2015, 31(8):717-722.
[14] 吴晋楠, 陈建荣, 陈金亮, 等. 肺癌肿瘤微环境中白细胞介素的研究进展[J]. 临床肺科杂志, 2019, 24(12):2280-2283.
[15] 李琬琼, 高艳锋. 抗肿瘤多肽药物研究进展[J]. 药学进展, 2019, 43(10):759-766.
Outlines

/